IL33 and neoplasm: Intra-tumoral IL-33 suppression may compromise local immune surveillance, while systemic IL-33 could represent a compensatory response to tumour progression, potentially influenced by host genetics such as IL-33 SNPs (e.g., rs1929992) (21–23).